Compare Abeona Therapeutics Inc (ABEO) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Colgate-Palmolive Company — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Colgate-Palmolive Company trades at $93.17 (market cap $76.04B). The key difference: Colgate-Palmolive Company is far larger — about 203.7× Abeona Therapeutics Inc's market cap, and Colgate-Palmolive Company pays a 2.23% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CL | |
|---|---|---|
Market Cap | $373.32M | $76.04B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $99.14 |
52-Week Low | $4.17 | $74.98 |
Enterprise Value | $228.22M | $82.68B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Colgate-Palmolive (CL) trades at $95.03, down 0.11% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company maintains strong profitability with a 60.06% gross margin and 10.04% net margin, though its P/E of 36.2 and P/B of 515.38 reflect premium valuation. Positive sentiment is driven by dividend consistency and strategic growth initiatives, while cash flow trends show stable operational performance.
Outlook remains cautiously optimistic with analyst consensus at Buy 42%, Hold 53%, and a $95.50 price target. Key opportunities include international growth and pricing power, but risks involve North American softness and high valuation multiples. The stock's 17% YTD gain underscores resilience, though inflation and competitive pressures warrant monitoring for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
